Clarient Diagnostic Services Inc, a GE Healthcare company, has modified its existing facility in Houston, Tex, to support a full range of clinical diagnostic testing for cancer. A CLIA-certified laboratory acquired by GE Healthcare in 2012, the facility previously operated under the name SeqWright Genomic Services, and offered nucleic acid sequencing and genomics capabilities services.
“The combined services offered in our Houston-based laboratory will enable Clarient and GE Healthcare to offer a substantially wider range of services to the biopharmaceutical, diagnostic, and research industries—and eventually to patients and healthcare providers,” said Cindy Collins, general manager at Clarient.
“This includes the ability to provide a substantially wider range of services which apply the power of new direct-detection technologies to clinical and companion diagnostics, potentially revolutionizing the way healthcare decisions are made,” she added. “The Houston lab expands our existing leadership position in comprehensive cancer testing, and is an exciting development for us.”
Clarient provides pathologists and oncologists with access to diagnostic tests that shed light on the complex nature of various cancers by combining innovative diagnostic technologies with pathology expertise to assess and characterize cancer. Clarient is focused on developing novel, proprietary diagnostic markers and tests for profiling breast, lung, colon, melanoma, and blood-based cancers, thereby helping clinicians make informed decisions on how best to treat their patients.
Clarient’s mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. Given the increasing importance of more-targeted cancer diagnostics, Clarient believes it is well positioned to bring differentiated, added-value molecular diagnostic products and services to market.
Announcement of the expansion in its laboratory services reinforces Clarient’s commitment to cancer and reflects its current integrated portfolio and GE Healthcare’s $1 billion R&D investment to advance oncology solutions by 2016. For more information, visit GE Healthcare and Clarient Diagnostic Services.
